Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.42 |
| ▸ | PPARA | Q07869 | 10/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966733 | 0.95 | PPARD (0.48) | PPARDPPARAPPARGFFAR4FFAR1 | |
| SCHEMBL3968890 | 0.88 | CYP11B1 (0.38) | PPARAPPARGFFAR4FFAR1 | |
| SCHEMBL3965811 | 0.83 | CYP11B1 (0.40) | PPARDPPARAPPARGFFAR4 | |
| SCHEMBL3966435 | 0.80 | FFAR1 (0.41) | PPARDPPARAFFAR1 | |
| SCHEMBL3965719 | 0.78 | PPARD (0.55) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL3961775 | 0.78 | FFAR4 (0.41) | PPARDPPARAPPARGFFAR4FFAR1 | |
| SCHEMBL3970524 | 0.77 | PPARD (0.43) | PPARDPPARAPPARGFFAR4FFAR1 | |
| SCHEMBL3965823 | 0.77 | PPARD (0.43) | PPARDPPARAPPARGFFAR4FFAR1 | |
| SCHEMBL3965826 | 0.77 | PPARD (0.43) | PPARDPPARAPPARGFFAR4FFAR1 | |
| SCHEMBL3970675 | 0.77 | FFAR4 (0.41) | PPARDPPARAPPARGFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | PPARD 88/4885PPARA 120/4885PPARG 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.